Bugitinib with venetoclax and cytarabine for relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm Phase 2 trial enrolling adults (18–70) with relapsed or refractory non-M3 AML. Treatment is induction with oral bugitinib plus oral venetoclax for 28 days combined with intravenous cytarabine for 7–10 days per cycle, with a possible second adjusted cytarabine cycle if complete remission is not achieved after the first cycle. The primary endpoint is the rate and durability of MRD negativity measured by bone marrow assessments, and MRD results will guide consolidation or maintenance decisions. Secondary endpoints include overall response rate (CR/CRi), overall survival, progression-free survival, and safety monitoring throughout therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet all of the following criteria:

* Age 18-70 years (inclusive), regardless of sex;
* Diagnosis of non-M3 acute myeloid leukemia (AML), and meeting at least one of the following conditions:

  * Failure to achieve complete remission (CR) after standard induction chemotherapy;
  * First CR duration ≤12 months;
  * First CR duration \>12 months, followed by relapse and failure of at least one line of standard chemotherapy;
  * Relapsed disease after ≥2 prior lines of therapy;
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
* Estimated life expectancy ≥3 months;
* Adequate organ function, defined as:

  * Cardiac: left ventricular ejection fraction (LVEF) ≥50% by echocardiography, with no clinically significant ECG abnormalities;
  * Renal: serum creatinine ≤2.0 × upper limit of normal (ULN) and creatinine clearance ≥60 mL/min (Cockcroft-Gault);
  * Hepatic: ALT and AST ≤3.0 × ULN;
  * Total bilirubin ≤2.0 × ULN (≤3.0 × ULN for patients with Gilbert syndrome);
  * Oxygen saturation ≥92% on room air;
* Ability to take oral medications and comply with study procedures;
* Willingness to participate and provide written informed consent.

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

* Known hypersensitivity to any study drug or its excipients;
* Active central nervous system (CNS) leukemia (patients with prior CNS involvement who achieved complete remission and are clinically stable may be eligible);
* Active, uncontrolled bacterial, viral, or systemic fungal infection;
* Known hereditary bleeding or coagulation disorders, history of non-traumatic bleeding or thromboembolism, or other conditions that may increase bleeding risk;
* Evidence of active infection, including:

  * Hepatitis B virus (HBV) infection with positive HBsAg or HBcAb and HBV DNA \>100 copies/mL;
  * Hepatitis C virus (HCV) antibody positive with detectable HCV RNA;
  * Human immunodeficiency virus (HIV) infection;
  * Positive test for syphilis;
* Active bleeding or clinically significant bleeding tendency, including but not limited to:

  * Active gastrointestinal bleeding, intracranial hemorrhage, or bleeding in other vital organs;
  * Grade ≥3 bleeding event within 4 weeks prior to enrollment (per CTCAE);
  * Known hereditary bleeding disorders (e.g., hemophilia);
  * Severe platelet dysfunction not correctable;
* Significant cardiovascular disease, including but not limited to:

  * New York Heart Association (NYHA) class III-IV heart failure;
  * Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment;
  * Clinically significant ventricular arrhythmias or unexplained syncope (excluding vasovagal or dehydration-related causes);
  * Severe cardiomyopathy;
* History of or concurrent other malignancies (except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix);
* Clinically significant central nervous system disorders (e.g., epilepsy, stroke, psychiatric disorders) that may affect compliance or safety;
* Participation in another interventional clinical trial within 30 days prior to enrollment;
* Pregnant or breastfeeding women, or subjects planning pregnancy during the study period or within 6 months after the last dose and unwilling to use effective contraception;
* Known or suspected drug abuse or alcohol dependence;
* Requirement for concomitant use of strong CYP3A inhibitors or inducers that cannot be discontinued or dose-adjusted per protocol;
* Any other condition that, in the investigator's opinion, would make the subject unsuitable for participation.

Where it's running

• Shenzhen University general hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Principal investigator: Shujiao He, Dr — Shenzhen University
• Study coordinator: Shujiao He, Dr
• Email: he_shujiao@126.com
• Phone: 075521837489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing high and low intensity therapies for relapsed or refractory acute myeloid leukemia

  This study is testing whether high-intensity chemotherapy works better than low-intensity treatments for people with relapsed or refractory acute myeloid leukemia.

  Recruiting at 39 sites Phase 3 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Brno and 50 other locations · NCT06713837

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML

  This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.

  Recruiting Phase 2 Maxinovel Pty., Ltd. · Tianjin · NCT07743112

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.